![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Bladder Cancer |
Free Subscription
1 Acta Biochim Biophys Sin (Shanghai) |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Acta Biochim Biophys Sin (Shanghai)
SOX5 promotes cell growth and migration through modulating the DNMT1/p21 pathway
in bladder cancer.
Acta Biochim Biophys Sin (Shanghai). 2022;54:1-12.
PubMed
Abstract available
Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based
cohort study.
Acta Oncol. 2022 Jul 26:1-9. doi: 10.1080/0284186X.2022.2101902.
PubMed
Abstract available
Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive
bladder cancer: a retrospective cohort study.
Acta Oncol. 2022 Jul 26:1-7. doi: 10.1080/0284186X.2022.2101381.
PubMed
Abstract available
Bladder Tissue Microbiome Composition in Patients of Bladder Cancer or Benign
Prostatic Hyperplasia and Related Human Beta Defensin Levels.
Biomedicines. 2022;10.
PubMed
Abstract available
Bacteria for Treatment: Microbiome in Bladder Cancer.
Biomedicines. 2022;10.
PubMed
Abstract available
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder
Cancer.
Bladder Cancer. 2022;8:101-112.
PubMed
Abstract available
Glycoprotein alpha-Subunit of Glucosidase II (GIIalpha) is a novel prognostic
biomarker correlated with unfavorable outcome of urothelial carcinoma.
BMC Cancer. 2022;22:817.
PubMed
Abstract available
A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder
cancer: a bioinformatics research.
BMC Urol. 2022;22:114.
PubMed
Abstract available
Current State of Cell Therapies for Genitourinary Malignancies.
Cancer J. 2022;28:294-300.
PubMed
Abstract available
An Integrated Bioinformatics Analysis towards the Identification of Diagnostic,
Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.
Cancers (Basel). 2022;14.
PubMed
Abstract available
Perioperative Complications and Oncologic Outcomes after Radical Cystectomy in
End-Stage Renal Disease Patients with Bladder Cancer Obtained Using a
Standardized Reporting System.
Cancers (Basel). 2022;14.
PubMed
Abstract available
Prognostic values of the immune microenvironment-related non-coding RNA
IGF2BP2-AS1 in bladder cancer.
Cell Cycle. 2022 Jul 27:1-17. doi: 10.1080/15384101.2022.2103898.
PubMed
Abstract available
Metastasis Within Three Years from Radical Nephroureterectomy as a Potential
Surrogate for Overall Survival.
Clin Genitourin Cancer. 2022;20:389.
PubMed
Abstract available
Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free
Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive
Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc
Analysis.
Clin Genitourin Cancer. 2022 Jun 25. pii: S1558-7673(22)00140.
PubMed
Abstract available
Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and
Urinary Diversion - A Propensity Score-matched Analysis.
Clin Genitourin Cancer. 2022;20:e283-e290.
PubMed
Abstract available
The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle
Invasive Bladder Cancer.
Clin Genitourin Cancer. 2022;20:e271-e275.
PubMed
Abstract available
Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients
Treated for Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2022;20:381-387.
PubMed
Abstract available
Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials
Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in
Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2022;20:e346-e352.
PubMed
Abstract available
Active surveillance for non-muscle-invasive bladder cancer: fallacy or
opportunity?
Curr Opin Urol. 2022 Jul 25. pii: 00042307-990000000-00032.
PubMed
Abstract available
Prevalence of Human Papilloma Virus Infection in Bladder Cancer: A Systematic
Review.
Diagnostics (Basel). 2022;12.
PubMed
Abstract available
A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into
Prescribed Molecular Subtypes and Predict Outcome.
Diagnostics (Basel). 2022;12.
PubMed
Abstract available
Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous
spread in high-grade urothelial carcinoma.
Eur J Nucl Med Mol Imaging. 2022;49:3571-3580.
PubMed
Abstract available
NEAT1/MALAT1/XIST/PKD--Hsa-Mir-101-3p--DLGAP5 Axis as a Novel Diagnostic and
Prognostic Biomarker Associated With Immune Cell Infiltration in Bladder Cancer.
Front Genet. 2022;13:892535.
PubMed
Abstract available
Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic
Implications in Bladder Cancer.
Front Immunol. 2022;13:909324.
PubMed
Abstract available
A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide
CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of
Bladder Cancer.
Front Immunol. 2022;13:908068.
PubMed
Abstract available
In silico development and experimental validation of a novel 7-gene signature
based on PI3K pathway-related genes in bladder cancer.
Funct Integr Genomics. 2022 Jul 28. pii: 10.1007/s10142-022-00884.
PubMed
Abstract available
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body
radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD
VACCINE MIBC trial.
Future Oncol. 2022;18:2771-2781.
PubMed
Abstract available
Prognostic value of preoperative platelet-related parameters and plasma
fibrinogen in patients with non-muscle invasive bladder cancer after
transurethral resection of bladder tumor.
Future Oncol. 2022 Jul 26. doi: 10.2217/fon-2022-0223.
PubMed
Abstract available
Effect of HER2 and Fascin expression on muscle-invasive bladder cancers:
Classification by basaloid and luminal phenotypes.
Indian J Pathol Microbiol. 2022;65:604-609.
PubMed
Abstract available
CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal
transition.
Int J Biol Sci. 2022;18:4275-4288.
PubMed
Abstract available
Nanodiamonds as Possible Tools for Improved Management of Bladder Cancer and
Bacterial Cystitis.
Int J Mol Sci. 2022;23.
PubMed
Abstract available
Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of
Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and
FGFR Target Gene Assessment.
Int J Mol Sci. 2022;23.
PubMed
Abstract available
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical
Practice? Part 2: Subtypes and Divergent Differentiation.
Int J Mol Sci. 2022;23.
PubMed
Abstract available
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical
Practice? Part 1: General Issues and Marker Expression.
Int J Mol Sci. 2022;23.
PubMed
Abstract available
Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX
Fluorescence in Bladder Cancer Cell Suspensions.
Int J Mol Sci. 2022;23.
PubMed
Abstract available
Anti-cancer properties of cannflavin A and potential synergistic effects with
gemcitabine, cisplatin, and cannabinoids in bladder cancer.
J Cannabis Res. 2022;4:41.
PubMed
Abstract available
Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched
Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes.
J Immunol. 2022;208:2829-2836.
PubMed
Abstract available
Sexual Activity, Function and Dysfunction After a Diagnosis of Bladder Cancer.
J Sex Med. 2022 Jul 20. pii: S1743-6095(22)01504.
PubMed
Abstract available
Whole-exome sequencing identified mutational profiles of urothelial carcinoma
post kidney transplantation.
J Transl Med. 2022;20:324.
PubMed
Abstract available
Sequential Intravesical Gemcitabine and Docetaxel for bacillus
Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer.
J Urol. 2022 Jul 27:101097JU0000000000002740. doi: 10.1097/JU.0000000000002740.
PubMed
Abstract available
Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial
Cancer Receiving Gene-Targeted Therapy.
JAMA Oncol. 2022;8:1070-1072.
PubMed
In-Silico Analysis of Deleterious SNPs of FGF4 Gene and Their Impacts on Protein
Structure, Function and Bladder Cancer Prognosis.
Life (Basel). 2022;12.
PubMed
Abstract available
Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following
Chemotherapy.
Medicina (Kaunas). 2022;58.
PubMed
Abstract available
[Corrigendum] MicroRNA335 is downregulated in bladder cancer and inhibits cell
growth, migration and invasion via targeting ROCK1.
Mol Med Rep. 2022;26.
PubMed
Abstract available
Clinicopathological and Prognostic Significance of Preoperative Prognostic
Nutritional Index in Patients with Upper Urinary Tract Urothelial Carcinoma.
Nutr Cancer. 2022;74:2964-2974.
PubMed
Abstract available
High prevalence of p16 staining in malignant tumors.
PLoS One. 2022;17:e0262877.
PubMed
Abstract available
The rate of prostatic involvement in men treated with radical cystectomy for
muscle invasive bladder cancer.
Pract Radiat Oncol. 2022 Jul 25. pii: S1879-8500(22)00193.
PubMed
Abstract available
Prognostic assessments in patients with upper tract urothelial carcinoma
undergoing radical nephroureterectomy and systematic regional lymph node
dissection.
Urologia. 2022;89:354-357.
PubMed
Abstract available
Use of ileal bypass in the surgical management of two rare cases of
ileal-neobladder fistula in patients who underwent radical cystectomy.
Urologia. 2022;89:488-492.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by